Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
HIK

Hikma Pharmaceuticals PLC

HIKLSEUnited KingdomHealthcareDrug Manufacturers - Specialty & GenericFTSE 250

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more

P/E11.39xP/B1.79xROIC12.4%Dividend yield4.0%
£3.28B
Market Cap
EV: £4.81B
MOM1
QUAL6
VAL8
RSK5
HIK
£3.28B
Market Cap · EV £4.81B

Hikma Pharmaceuticals PLC

MOM1
QUAL6
VAL8
RSK5

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more

Latest RNS from Hikma Pharmaceuticals PLC

Analyst consensus: Buy

As of 21 Jul 2026, 12 analysts rate Hikma Pharmaceuticals PLC a Buy, with 92% buy ratings and a mean price target of 1,850p (range 1,325p–2,637p), +20% vs the current price.

Strong buy: 3Buy: 8Hold: 0Sell: 0Strong sell: 1

Full analyst history →

Valuation vs peers

Peer-relative fair value estimate: 3,782p against a current price of 1,540p (+146%), based on EV/EBITDA.

More Healthcare companies